Back to results

CompletedPhase 3

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia

NCT02274766

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Fountain Valley, California, United States

+50 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2014-10
Enrollment: 77 participants
Sponsor: Adamas Pharmaceuticals, Inc.
Purpose: treatment

Locations (51)

Fountain Valley, California, United States
Sunnyvale, California, United States
Boca Raton, Florida, United States
Jacksonville, Florida, United States
Port Charlotte, Florida, United States
Sunrise, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Kansas City, Kansas, United States
Baltimore, Maryland, United States
Elkridge, Maryland, United States
Boston, Massachusetts, United States
West Bloomfield, Michigan, United States
Greensboro, North Carolina, United States
Raleigh, North Carolina, United States
Tulsa, Oklahoma, United States
Roanoke, Virginia, United States
Kirkland, Washington, United States
Morgantown, West Virginia, United States
Milwaukee, Wisconsin, United States
Innsbruck, Austria
Vienna, Austria
Vienna, Austria
Bordeaux, France
Bron, France
Clermont-Ferrand, France
Lille, France
Marseille, France
Montpellier, France
Poitier, France
Rennes, France
Rouen, France
Strasbourg, France
Toulouse, France
München, Bavaria, Germany
München, Bavaria, Germany
Beelitz-Heilstätten, Brandenburg, Germany
Göttingen, Lower Saxony, Germany
Leipzig, Saxony, Germany
Gera, Thuringia, Germany
Stadtroda, Thuringia, Germany
Berlin, Germany
Berlin, Germany
Hamburg, Germany
Kassel, Germany
Marburg, Germany
Barcelona, Spain
Barcelona, Spain
Barcelona, Spain
Barcelona, Spain

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia — TrialFind